Allogene Therapeutics Adds Immunotherapy Luminaries, Thomas F. Gajewski, M.D., Ph.D., and Stephan Grupp, M.D., Ph.D., to its Scientific Advisory Board
“We are privileged to welcome Drs. Gajewski and Grupp to our
New Allogene SAB members:
Thomas F. Gajewski , M.D., Ph.D. is the AbbVie Foundation Professor in Cancer Immunotherapy and practicing physician at theUniversity of Chicago . Throughout his career Dr. Gajewski’s work has focused on understanding fundamental aspects of anti-tumor immunity and bringing these concepts forward from the laboratory into clinical trial testing in patients. Under Dr. Gajewski’s leadership, his laboratory uncovered a role for downstream resistance pathways allowing tumor evasion from the immune response. An author of more than 250 manuscripts, 20 book chapters, and a speaker at over 200 scientific conferences,Dr. Gajewski has served as past president of theSociety for Immunotherapy of Cancer , is founding editor of theJournal for Immunotherapy of Cancer , is past chair of the Cancer Immunopathology and Immunotherapy grant review study section at theNational Institutes of Health (NIH), has served on the program committees for theAmerican Society of Clinical Oncology (ASCO) and theAmerican Association forCancer Research (AACR), and is a grant reviewer for theMelanoma Research Alliance andCancer Research Institute .Dr. Gajewski has been honored with numerous awards and recognitions and in 2015 was designated a Distinguished Professor at theUniversity of Chicago . He holds a B.S., Ph.D. in Immunology, and M.D. degrees from theUniversity of Chicago .
Stephan Grupp , M.D., Ph.D. is the Novotny Professor of Pediatrics and co-lead of theAbramson Cancer Center pediatrics program at theUniversity of Pennsylvania Perelman School of Medicine . He also serves as the Section Chief of Cellular Therapy and Transplant inDivision of Oncology , Director of the Cancer Immunotherapy Program, and Medical Director of theCell and Gene Therapy Lab at the Children’s Hospital ofPhiladelphia . His primary area of clinical research is the use of CAR T and other engineered cell therapies in pediatric cancers and other disorders such as sickle cell disease. He led all of the pediatric/young adult ALL trials of CTL019, now approved by theU.S. Food and Drug Administration as Kymriah® (tisagenlecleucel), as well as the global registration trial for CTL019 (NEJM 2013, 2014, 2018). His primary laboratory interest is the development of new cell therapy treatments for pediatric cancers. Over 200 scientific publications have been generated by Dr. Grupp’s research, and he has received numerous achievement and impact awards for his contributions to the cell therapy and oncology fields, including his election to theNational Academy of Medicine in 2019.Dr. Grupp received his M.D. and his Ph.D. from theUniversity of Cincinnati College of Medicine and completed multiple fellowships atHarvard Medical School , Boston Children’s Hospital, theDana Farber Cancer Institute and Children’s Hospital and Brigham and Women’s Hospital.
The new advisors join existing
About
Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T therapies for cancer and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the
Kymriah® is a registered trademark of
AlloCAR T™ is a trademark of
Allogene Media/Investor Contact:
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com
Source: Allogene Therapeutics, Inc.